(Date:7/3/2009)... , ReverseAges.com launch...lood pressure, adrenal fatigue, and how to best de... San Diego, CA (PRWEB) July 3, 2009 -- Revers...ges. These pages explain the dangers of common hea... pressure is caused by a variety of factors, and t...
(Date:7/2/2009)... , Scientists at Singapore,s Bioprocessing Techno...bout how the gene, "Fas-apoptosis inhibitory molec...from apoptosis, or programmed cell death. , The...ell Death and Differentiation . , The scientists...discovered that this process may possibly be manip...
(Date:7/2/2009)... , LITTLE SILVER, N.J., July 2 ...logist is coordinating a new study to measure the ...treatment of acute EKC -- a common, worldwide, hig...itis with the potential for long term visual impai...logists around the world are invited to register t...
(Date:7/2/2009)... When the sleep aid shuts down one set of neurons...AY, July 2 (HealthDay News) -- New information ab...me people who take the sleep aid Ambien (zolpidem)... not fully awake -- and without remembering it the...o awaken minimally conscious patients into a consc...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2(Date:6/29/2009)..., SOUTHAMPTON, England, June 29 /PRNewswire/ ...l company developing novel, small molecule drugs,...unces positive results from,a Phase IIa clinical ...r,nocturia. The trial showed that oral VA106483 w...ained anti-diuretic effect in patients, as determi...
(Date:6/26/2009)..., DEERFIELD, Ill., June 26, and OSAKA, Japan, Jun...ompany Limited ("Takeda") today announced that Tak..., a wholly owned United States (U.S.) subsidiary r... letter from the U.S. Food and Drug Administration...n (NDA) for alogliptin, a selective dipeptidyl pep...
(Date:6/26/2009)..., Positive Opinion Recommends Approval of New Ant...el SmartJect(TM) Autoinjector , , HORSHAM, Pa. ...l/ -- Centocor Ortho Biotech Inc. and Schering-Plo...t the Committee for Medicinal Products for Human U...adopted a positive opinion recommending the approv...
(Date:6/25/2009)..., Company Also Receives Patent Covering ARIKACE f...ions , , MONMOUTH JUNCTION, N.J., June 25 /PRNe... Inc., the nonprofit affiliate of the Cystic Fibro...to Transave Inc., for the continued development of...an antibiotic that aims to treat Pseudomonas lun...
Breaking Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4Genes influence effectiveness of weight loss drug 26917 1Genes influence effectiveness of weight loss drug 26917 2Genes influence effectiveness of weight loss drug 26917 3Hay fever may be best treated with self adjusted dosing 26915 1Hay fever may be best treated with self adjusted dosing 26915 2Asian white couples face distinct pregnancy risks Stanford Packard 26913 1Asian white couples face distinct pregnancy risks Stanford Packard 26913 2Asian white couples face distinct pregnancy risks Stanford Packard 26913 3Cylex 28TM 29 Receives ISO 13485 3A2003 and 9001 3A2000 Quality Certifications 8004 1Cylex 28TM 29 Receives ISO 13485 3A2003 and 9001 3A2000 Quality Certifications 8004 2... 2007 /PRNewswire-FirstCall/ --,NeurogesX, Inc. an...om a positive Phase 3 trial in postherpetic neural...r of Neurology at University,of Wisconsin in Madis... trial, plans to present the results of the study ...onal Congress on,Neuropathic Pain in Berlin, Germa...
...7 /PRNewswire-FirstCall/ -- Vanda,Pharmaceuticals ...f,the Henry Ford Sleep Disorders and Research Cent...on on recent Phase III clinical,trial results for ...ptor agonist, at SLEEP 2007, the 21st annual meeti... (APSS). , The Vanda presentation will take place ...
Other Medicine Technology:NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies 2Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and
This blanket gently surrounds the child with temperature-controlled air. Use one or both of the enclosed clear plastic drapes to keep warmed air near the skin.
2-ply material consisting of polyethylene film inner layer and non-woven outer layers.
This unique blanket is designed to be used for many surgical procedures, including but not limited to: laminectomies, spinal procedures, abdominal procedures, and transplants.
Medicine Products: